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To the Editor
We thank Cottin et al. for their interest in our work [1],
and for sharing their engaging thoughts. They noted
that our results appear to be in contrast with previous
studies, and cite three references in support [2-4]. We
agree that on the surface, there may be apparent dis-
agreement with some previous results, but in-depth ana-
l y s i sd o e sn o ts u g g e s ti n c o n s i s t e n c yb e t w e e nf i n d i n g s
made by various groups of investigators.
In the study by Cottin et al.[ 2 ] ,p a t i e n t sw i t hc o m -
bined pulmonary fibrosis and emphysema had a median
survival of 6.1 years, a very similar survival time to our
patients with advanced centrilobular emphysema com-
bined with pulmonary fibrosis, who had a median survi-
val of 6.2 years (75 months). Thus, these two reports are
in full agreement on the duration of patient survival.
However, contrasting the findings of both of these stu-
dies is another study of patients with idiopathic pulmon-
ary fibrosis (IPF) and emphysema [3]. Of important note
in this study, patients in the IPF and emphysema group
had a median history of smoking of 5 pack-years,
whereas in our study, patients with advanced emphy-
sema and pulmonary fibrosis had a median 40 pack-year
history of smoking. Because heavy cigarette smoking has
been suggested to play a causative role in patients who
develop emphysema combined with pulmonary fibrosis,
it is not surprising that the outcomes differed between
this study and our report. Further input on survival in
patients with pulmonary fibrosis and emphysema comes
from Antoniou et al. [4], who reported that ‘findings
were unchanged when the presence of emphysema ...
was taken into account in survival analysis, with the pre-
sence of emphysema having no influence on survival.’
However, this study focused not on patients with
emphysema combined with fibrosis, but rather on com-
paring patients with IPF who were smokers versus those
who were non-smokers. Smoking and emphysema are
certainly associated, but these are two separate popula-
tions of patients that should not be equated.
Taking together all the observations in these four stu-
dies [1-4], it appears that generalized conclusions on
survival of patients with emphysema combined with pul-
monary fibrosis should be avoided, as survival varies
depending on the specific characteristics of patient sub-
populations being studied. In our work specifically [1],
the mere presence of emphysema in patients with pul-
monary fibrosis did not equate to better survival, and
only a subpopulation of our patients (those with an
advanced centrilobular component to their emphysema)
survived longer, as we reported in detail.
The presence of non-specific interstitial pneumonia
(NSIP) in our group of patients with advanced emphy-
sema and pulmonary fibrosis was discussed, although
the patterns of usual interstitial pneumonia (UIP)/NSIP
were not significantly different between the groups in
our study. The attempt to extrapolate percentages of
pathologic patterns to patients from whom a surgical
lung biopsy was not obtained is inconsistent with the
scientific method. A strength of our study is the large
portion of patients (70%) from whom surgical lung tis-
sue was available for pathologic examination, both in
the entire cohort and in the advanced emphysema with
* Correspondence: ntodd@medicine.umaryland.edu
University of Maryland School of Medicine and Baltimore VA Medical Center,
Baltimore, MD, USA
Todd and Atamas Fibrogenesis & Tissue Repair 2011, 4:17
http://www.fibrogenesis.com/content/4/1/17
© 2011 Todd and Atamas; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.fibrosis group. This is in contrast to two previous stu-
dies of patients with combined pulmonary fibrosis
and emphysema, in which only approximately 15% of
patients had histological analysis of surgical or explanted
lung tissue [2,5].
The handling, with regard to survival analysis, of
patients in our study who underwent lung transplanta-
tion is also discussed. As suggested, we censored
patients who underwent lung transplantation, and per-
formed survival analyses. Comparison of survival curves
by log rank tests showed improved survival in patients
with pulmonary fibrosis and advanced emphysema com-
pared with patients with pulmonary fibrosis without
emphysema (P = 0.014) and patients with pulmonary
fibrosis and trivial emphysema (P = 0.015). There was
no survival difference between patients with pulmonary
fibrosis without emphysema and patients with fibrosis
and trivial emphysema (P = 0.776). Therefore, our origi-
nal findings remained the same when patients who
underwent transplantation were censored for the statis-
tical analysis.
Cottin et al. question the severity of fibrosis in our
advanced emphysema and fibrosis group, based on an
interpretation of our DLCO (diffusing capacity of the
lung for carbon monoxide) findings. It is possible, in the
absence of data on total lung collagen, that the lack of
difference in DLCO between groups could be due to dif-
ferences in the amount of fibrosis. Direct estimation of
total lung collagen in humans is obviously challenging,
and we thus used an accepted visual fibrosis score, as
described [1]. It is, however, important to keep in mind
that although both emphysema and fibrosis cause reduc-
tions in DLCO, there is often a loose statistical associa-
tion between severity of emphysema or fibrosis
determined by visual scores and the severity of the
reductions in DLCO [6,7]. The expectation of a strict
correlation between emphysema or fibrosis scores and
DLCO is not justified based on these observations.
Overall, our study does not appear to be inconsistent
with the existing body of literature concerning patients
with emphysema combined with pulmonary fibrosis, and
it expands further the factual knowledge in this field.
There are certainly aspects of our study that are open to
scientific speculation, but we identified those (for exam-
ple, a possibility that pulmonary inflammation resulting
from the presence of emphysema may be partially pro-
tective against the deleterious effects of pulmonary
fibrosis) in the discussion section of our report.
In summary, emphysema combined with pulmonary
fibrosis is likely to be a heterogenous entity, in which
survival is defined by characteristics of specific patient
subpopulations. In our cohort of patients, survival was
improved when advanced centrilobular emphysema was
present in patients with pulmonary fibrosis.
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